Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.45% |
| 2 | Technology | 16.09% |
| 3 | Consumer Staples | 10.57% |
| 4 | Consumer Discretionary | 9.95% |
| 5 | Communication Services | 9.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
976
Puma Biotechnology
PBYI
$450M
| $15.3M | 0.01% |
1,465,697
+377,100
| +35% | +$3.9M |
|
|
CCXI
977
DELISTED
ChemoCentryx, Inc.
CCXI
| $15.3M | 0.01% |
265,100
-58,200
| -18% | -$3.17M |
|
978
Independent Bank Corp
IBCP
$854M
| $15.2M | 0.01% |
1,024,200
-10,600
| -1% | -$146K |
|
|
BFS
979
Saul Centers
BFS
$850M
| $15.2M | 0.01% |
470,174
-111,000
| -19% | -$3.54M |
|
980
Ligand Pharmaceuticals
LGND
$5.76B
| $15.2M | 0.01% |
217,277
-744,433
| -77% | -$47.2M |
|
981
Great Southern Bancorp
GSBC
$877M
| $15.1M | 0.01% |
374,600
-13,700
| -4% | -$542K |
|
|
GCAP
982
DELISTED
Gain Capital Holdings, Inc.
GCAP
| $15.1M | 0.01% |
2,511,104
+1,413,300
| +129% | +$8.7M |
|
|
VSTO
983
DELISTED
Vista Outdoor Inc.
VSTO
| $15.1M | 0.01% |
1,046,000
-166,500
| -14% | -$1.67M |
|
984
Paysign
PAYS
$723M
| $15.1M | 0.01% |
1,555,150
-330,300
| -18% | -$2.44M |
|
985
News Corp Class B
NWS
$17.7B
| $15.1M | 0.01% |
1,262,653
-209,300
| -14% | -$2.27M |
|
986
Williams Companies
WMB
$90.1B
| $15.1M | 0.01% |
+793,285
| New | +$14.8M |
|
987
Liquidity Services
LQDT
$1.35B
| $15M | 0.01% |
2,523,972
+156,508
| +7% | +$830K |
|
|
PPL
988
PPL Corp
PPL
$26.7B
| $15M | 0.01% |
580,900
-3,144,131
| -84% | -$81.8M |
|
|
CEL
989
DELISTED
Cellcom Israel, Ltd.
CEL
| $15M | 0.01% |
3,831,642
+15,900
| +0.4% | +$55.4K |
|
990
Brown-Forman Class A
BF.A
$13B
| $14.9M | 0.01% |
258,600
-8,629
| -3% | -$503K |
|
|
Y
991
DELISTED
Alleghany Corp
Y
| $14.8M | 0.01% |
30,188
+7,300
| +32% | +$3.78M |
|
992
First Industrial Realty Trust
FR
$8.4B
| $14.7M | 0.01% |
382,900
-294,601
| -43% | -$10.8M |
|
993
Strategy Inc
MSTR
$38.2B
| $14.7M | 0.01% |
1,244,000
+940,000
| +309% | +$11.4M |
|
|
AGR
994
DELISTED
Avangrid, Inc.
AGR
| $14.6M | 0.01% |
347,741
-836,800
| -71% | -$35.9M |
|
995
Lakeland Industries
LAKE
$119M
| $14.6M | 0.01% |
649,802
+9,400
| +1% | +$154K |
|
996
Unilever
UL
$135B
| $14.6M | 0.01% |
235,822
-536,408
| -69% | -$32.1M |
|
997
Equifax
EFX
$21.2B
| $14.6M | 0.01% |
+84,695
| New | +$12.5M |
|
|
IVC
998
DELISTED
Invacare Corporation
IVC
| $14.5M | 0.01% |
2,283,969
-63,700
| -3% | -$426K |
|
999
Curtiss-Wright
CW
$25.4B
| $14.5M | 0.01% |
162,900
+3,125
| +2% | +$298K |
|
1000
Cimpress
CMPR
$2.4B
| $14.5M | 0.01% |
190,300
-39,100
| -17% | -$2.78M |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 25% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.